Chaperon Presents Preclinical Results of Atopic Dermatitis Drug Candidate at European Conference Poster Session

[Asia Economy Reporter Lee Gwan-ju] Chaperon announced on the 6th that it presented key preclinical data of the atopic dermatitis treatment 'NuGel' in a poster session at the European Federation for Medicinal Chemistry - International Symposium on Medicinal Chemistry (EFMC-ISMC 2022) held in Nice, France.

NuGel is being developed as a new drug candidate for mild to moderate atopic dermatitis patients. It has a mechanism that suppresses atopic dermatitis through activation of the receptor ‘G protein-coupled receptor 19 (GPCR19)’, which regulates the occurrence of inflammation.

Chaperon is developing anti-inflammatory treatments based on its proprietary inflammasome inhibition technology to treat inflammatory diseases such as atopic dermatitis, Alzheimer's dementia, idiopathic pulmonary fibrosis, and COVID-19.

Following last year's technology transfer with Kukjeon Pharmaceuticals for an Alzheimer's dementia treatment, in the first half of this year, Chaperon completed a technology transfer to Bridge Biotherapeutics based on successful preclinical results in idiopathic pulmonary fibrosis, a severe rare disease.

A Chaperon official stated, “Through this presentation, we aim to highlight the strengths of Chaperon's inflammasome inhibitors and proceed with clinical trials sequentially so that NuGel can become a new alternative for atopic dermatitis treatment.”

This content was produced with the assistance of AI translation services.